ATRIAL FIBRILLATION

ATRIAL FIBRILLATION 

Atrial fibrillation is a supraventricular tachyarrhythmia characterized by:

• Irregularly irregular rhythm(One exception to these criteria is that if AF is combined with heart block, then the ventricular response may be regular.)
• No distinct P waves(If it is unclear whether there are P waves or fibrillation waves, consider obtaining a Lewis Lead ECG)
• Fibrillatory (f) waves
• Variable R–R intervals

CLASSIFICATION 

 Also:

• Valvular AF → moderate–severe mitral stenosis / mechanical valve
• Non-valvular AF → all others

 TYPES OF AF BASED ON VENTRICULAR RESPONSE

PATHOPHYSIOLOGY

• Most commonly from pulmonary veins
• Focal ectopic activity
• Multiple re-entry circuits
• Electrical remodeling:
• ↓ refractory period
• “AF begets AF”

ETIOLOGY

CARDIAC

• Hypertension (most common)
• CAD 
• Pericarditis
• Heart failure
• Valvular disease (esp. mitral stenosis)
• Cardiomyopathy

NON-CARDIAC

• Hyperthyroidism
• Obesity 
• OSA
• Alcohol (“holiday heart”)
• Substance use (especially cocaine, amphetamine, methamphetamine).
• CKD

ICU-SPECIFIC

• Volume overload
• Beta-agonists (norepinephrine, epinephrine, dobutamine).therefore as vasoconstricter use phenylephrine, vasopressin.
• Sepsis
• Primary neurologic disorders (e.g., intracranial hemorrhage, ischemic stroke)
• Postoperative state (especially cardiothoracic surgery).
• Pain and anxiety( treat with dexmedetomidine)

CLINICAL FEATURES

Symptoms

• Palpitations
• Dyspnea
• Fatigue
• Dizziness
• Syncope (rare)

Signs

• Irregularly irregular pulse
• Pulse deficit
• Variable S1

COMPLICATIONS

1. THROMBOEMBOLISM

• Stroke risk ↑ 5-fold
• Left atrial appendage thrombus

2. HEART FAILURE

• Loss of atrial kick
• Tachycardia-induced cardiomyopathy

DIAGNOSIS

• 12-lead ECG documentation ≥30 secIn 
• Most patients not receiving AV nodal blocking drugs, atrial fibrillation typically presents with a ventricular rate of 120–180 beats/min.
• A very rapid ventricular rate (>200 beats/min) should raise suspicion for an accessory pathway, such as atrial fibrillation with Wolff–Parkinson–White (WPW) syndrome.
• A ventricular rate <100 beats/min in untreated AF may suggest underlying AV nodal or conduction system disease.

Workup:

• Echocardiography
• Thyroid function tests
• Electrolytes(magnesium,potasium)-administration of magnesium(if kidney is normal) doesn’t need to wait until the level returns.
• Renal function
• Holter if paroxysmal

Is Atrial Fibrillation the Cause or the Consequence of Hemodynamic Instability?

The most important question in a patient with atrial fibrillation (AF) and hemodynamic instability is whether AF is the primary cause of the instability or simply a manifestation of an underlying critical illness.

This distinction is crucial because electrical (DC) cardioversion is most likely to improve the patient’s condition only when AF itself is responsible for the hemodynamic compromise. Examples include new-onset AF with a very rapid ventricular response leading to hypotension, myocardial ischemia, pulmonary edema, or shock.

In many critically ill patients, however, AF develops secondary to conditions such as sepsis, hypovolemia, hypoxia, pulmonary embolism, acute heart failure, or postoperative stress. In these situations, the tachycardia may represent a physiological compensatory response aimed at maintaining cardiac output and tissue perfusion.

MANAGEMENT

1.  INITIAL APPROACH (ICU /EMERGENCY)

 Hemodynamically unstable AF

• Hypotension
• Shock
• Pulmonary edema
• Ongoing ischemia
• Altered mental status

 Immediate treatment = synchronized DC cardioversion

• Biphasic:Use the maximal energy available (e.g., 200-360 J)
• anterior–lateral pad positioning is more effective than anterior–posterior pad placement.
• In mechanically ventilated patients or those with significant lung hyperinflation, the effectiveness of electrical cardioversion may be reduced because hyperinflated lungs increase transthoracic impedance and impair transmission of electrical current to the myocardium.To improve cardioversion success:

• Deliver the shock at end-expiration, when lung volume and thoracic impedance are lowest.
• In patients with marked hyperinflation or excessive positive-pressure ventilation, brief ventilator disconnection before shock delivery may allow chest deflation and improve current delivery, provided that oxygenation and hemodynamic status permit.

• Amiodarone can be used both before and after electrical cardioversion to increase the likelihood of successful conversion to sinus rhythm and to reduce the risk of early recurrence of atrial fibrillation.
• In critically ill patients, amiodarone is often continued after successful cardioversion until the underlying illness has resolved, typically for 1–2 weeks, as the risk of recurrent atrial fibrillation remains high during the acute phase of critical illness.
• Intravenous magnesium is another valuable adjunct and should be considered in most patients, particularly when magnesium deficiency is suspected or when atrial fibrillation is difficult to control.
• Sedation-midazolam 3-5 mg IV bolus (depending on age, weight) if resistant add 50mg ketamine.
• Start anticoagulation as soon as feasible.

Stable Patient → Decide Strategy

 Rate control vs Rhythm control

2. RATE CONTROL (FIRST-LINE IN MOST)

• Best works in Chronic AF,AF >48 hours previously, in a patient who isn’t anti-coagulated
• Target-Resting HR <110 bpm (The optimal heart rate for critically ill patients is unknown.)

1.  Beta-blockers 

• Metoprolol
• IV: 2.5–5 mg over 2 min (repeat q5 min, max 15 mg)
• Oral: 25–100 mg BD
• Esmolol 
• Bolus: 500 mcg/kg
• Infusion: 50–200 mcg/kg/min

 Preferred in:Post-MI,Hyperadrenergic states

2.  Non-DHP Calcium Channel Blockers(Avoid in: HFrEF)

• Diltiazem
• IV bolus: 0.25 mg/kg
• Repeat: 0.35 mg/kg
• Infusion: 5–15 mg/hr
• Verapamil IV: 5–10 mg slow

3.  Digoxin

• Loading: 0.5 mg → 0.25 mg q6h (max 1–1.5 mg)
• Maintenance: 0.125–0.25 mg/day

 Best in:HF with low BP,Sedentary patients

 Not effective in high sympathetic tone

4.  Amiodarone (most common choice)

• IV: 150 mg over 10 min( to achieve rate control you can reload with 150 mg amiodarone every 20–30mins for  2-3 times )
• Then: 1 mg/min × 6 hr → 0.5 mg/min
• after >24 hours Oral: 400 mg BD until the patient has received a total of 10 grams cumulative dose (IV plus PO)→ taper 200 mg daily.
• Can not keep patient on this for long term due to side-effects therefore eventually switch to another agent (e.g., a beta-blocker).
•  Preferred in:HFrEF,ICU unstable rate

NOTE-Failure of one rate-control drug ≠ failure of the rate-control strategy.

Switch to or add another rate-control agent depending on the clinical scenario:

• Digoxin (especially if hypotensive or HFrEF).
• Diltiazem/verapamil (Avoid combining beta-blockers and calcium-channel blockers).
• Amiodarone (common in ICU patients when other agents fail or are poorly tolerated).
• Addition of magnesium.

Long-Term Rate Control

3.  RHYTHM CONTROL(CARDIOVERSION)

Indications 

• Symptomatic AF despite rate control
• New-onset AF
• AF worsens function by loosing atrial kick i.e Valvular heart disease (especially mitral stenosis),Diastolic dysfunction,Heart failure with reduced ejection fraction. 
• Atrial flutter
• AF< 48 hr

PHARMACOLOGICAL 

1. Amiodarone

• 300 mg over 20–60 minutes with additional boluses as needed up to a total of ~450-600 mg administered in boluses or 5–7 mg/kg IV over 1–2 hours.
• followed by an infusion at ~1 mg/min 
• Conversion may take hours,Sometimes takes 24–48 hours

2. Flecainide(Avoid in:Structural heart disease)

• Oral: 200–300 mg single dose
• IV: 2 mg/kg

3. Propafenone—Oral: 450–600 mg

4. Ibutilide—1 mg IV over 10 min

 Risk: Torsades de pointes

5.Magnesium infusion– 4 g IV over 60 minutes Followed by maintenance infusion 1gm/hour for 24 hours .but if If GFR <30 ml/min, intermittent boluses may be used to target a level of ~3-4 mg/dL.

ELECTRICAL 

• Biphasic: 200-360 J(use max energy)

Long-Term Rhythm Control Drugs in Atrial Fibrillation (AF)

4. ANTICOAGULATION 

• Risk scores(e.g., CHA2DS2-VASc, HAS-BLED) for bleeding and thrombosis are validated for chronic/non-valvular AF in ambulatory populations not for ICU.
• Chronic AF anticoagulation may be considered similarly to that of outpatients
• NOAF due to critical illness-grey area as anticoagulation increases the risk of bleeding

Stroke Risk → CHA₂DS₂-VASc helps determine whether long-term anticoagulation is indicated.

INTERPRETATION 

 HAS-BLED score

It estimates 1-year risk of major bleeding, especially:

• Intracranial hemorrhage
• GI bleeding
• Major extracranial bleeding

 Max score = 9

INTERPRETATION

HAS-BLED is NOT used to deny anticoagulation

According to ESC 2023 / AHA 2023:

• High HAS-BLED (≥3) →DO NOT stop anticoagulation
   Instead:Correct risk factors,Monitor closely

ANTICOAGULATION OPTIONS

1.  DOACs (FIRST LINE in outside ICU )

• Apixaban
• 5 mg BD
• 2.5 mg BD if ≥2: age ≥80, wt ≤60, Cr ≥1.5
• Rivaroxaban
• 20 mg OD
• 15 mg if CKD
• Dabigatran
• 150 mg BD
• 110 mg BD (elderly/high bleeding risk)

2.  Vitamin K antagonist

• Warfarin–INR target: 2–3

Indications:

• Mechanical valves
• Moderate–severe mitral stenosis

3. Unfractionated Heparin (UFH) – Usually Preferred in Unstable ICU Patients

Dose

• Bolus: 60–80 U/kg (often omitted in high bleeding risk)
• Infusion: 12–18 U/kg/hr
• Target:
• aPTT 1.5–2.5 × control
• or anti-Xa 0.3–0.7 IU/mL

 Low-Molecular-Weight Heparin (LMWH)

Examples:Enoxaparin,Dalteparin

• Enoxaparin 1 mg/kg SC every 12 hr or 1.5 mg/kg once daily

ANTICOAGULATION AROUND CARDIOVERSION Electrical or Chemical (pharmacologic) and  regardless of CHA₂DS₂-VASc score.

AF → blood stasis in left atrium.Cardioversion → atrial contraction resumes.Restoring sinus rhythm  can dislodge a left atrial thrombus → stroke risk.

• AF <48 hr—Heparin in ICU patient/DOAC for outside ICU→ cardioversion
• AF >48 hr or unknown —Anticoagulate ≥3 weeks OR TEE-guided cardioversion(check left atrial/left atrial appendage for thrombus)
• Post cardioversion-Continue ≥4 weeks

5.  SPECIAL SCENARIOS 

AF + WPW 

 Avoid AV node blockers:

• Beta-blocker
• Diltiazem
• Digoxin

 Use:

• Procainamide
• Electrical cardioversion

AF + SEPSIS / ICU

• First treat cause
• Amiodarone preferred
• Avoid aggressive beta-blockade in shock

Post-operative AF

• Beta-blockers first line
• Amiodarone if needed

6. NON-PHARMACOLOGICAL MANAGEMENT

1.  CATHETER ABLATION (CORNERSTONE)

AF is most commonly triggered by ectopic foci from pulmonary veins (PVs) → isolate them electrically.

PROCEDURE: PULMONARY VEIN ISOLATION (PVI)

Techniques:

• Radiofrequency ablation (point-by-point lesions)
• Cryoballoon ablation (freezing PV ostia)

 INDICATIONS 

 Class I (STRONG RECOMMENDATION)

• Symptomatic paroxysmal AF refractory/intolerant to ≥1 antiarrhythmic drug
• Symptomatic persistent AF (selected cases)

 Class IIa 

• First-line therapy in:
• Young patients
• Symptomatic AF
• Patient preference
• AF with heart failure (HFrEF) → improves:
• EF
• Symptoms
• Mortality (CASTLE-AF evidence)

 COMPLICATIONS 

• Cardiac tamponade
• Stroke / TIA
• Pulmonary vein stenosis
• Atrio-esophageal fistula (rare but fatal)
• Phrenic nerve injury (cryoablation)

 GUIDELINE PEARLS

• Early rhythm control (including ablation) improves outcomes
• Preferred over drugs in selected patients
• Continue anticoagulation based on CHA₂DS₂-VASc (not rhythm success)

2. AV NODE ABLATION + PACEMAKER (“ABLATE & PACE”)

• Destroy AV node → eliminate rapid ventricular response
• Implant pacemaker → maintain heart rate

 INDICATIONS

• Refractory AF with uncontrolled rate
• Intolerance to drugs
• Tachycardia-induced cardiomyopathy

 TYPES OF PACING

• RV pacing (traditional)
• CRT (biventricular pacing) → preferred in HF
• His-bundle pacing (physiological pacing)

 LIMITATIONS

• Patient becomes pacemaker dependent
• AF persists (no rhythm control)
• Anticoagulation still required

4.  LEFT ATRIAL APPENDAGE (LAA) OCCLUSION

• Most thrombi in AF originate in left atrial appendage

 INDICATIONS

• AF + contraindication to long-term anticoagulation
• High bleeding risk

• Not first-line
• Short-term anticoagulation still needed post-procedure

5. SURGICAL MANAGEMENT

 MAZE PROCEDURE

• Create scar lines → block reentry circuits

INDICATIONS

• AF undergoing cardiac surgery (e.g., valve surgery)
• Failed catheter ablation

TRIALS 

REFERENCES

1.European Society of Cardiology (ESC)

• Hindricks G, et al.
• 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation.

2.AHA guidelines

3.Oxford handbook of internal medicine